Iris Ziegler

This inventor holds 17 USPTO granted patents and 7 published patent applications, plus 3 CIPO patents and 2 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Gruenenthal Gmbh, Grunenthal Gmbh. Active years: 2002-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Iris Ziegler. Retrieved from https://idiyas.com/inventor/iris-ziegler

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 7)

% Patents Active = 29.4

CIPO Patents = 3

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 2.5

ph-index = 10

Forward Citations = 258(Granted Patents)

Location History:

Roetgen, DE (2010 - 2014)
Neusäβ, DE (2013 - 2017)
Rott-Roetgen, DE (2002 - 2021)

Company Filing History:

Years Active: 2002-2021

Loading Chart...

Areas of Expertise:

Pharmaceutical Composition

Dosage Form

Sustained-Release

Controlled Release

Multi-Particulate

Fast Release

Oral Administration

Coated Pellets

Tramadol

Diclofenac

Cefuroximaxetil

Abuse Deterrent

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11007156 - Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol (2021-05-18),

2. 9750701 - Pharmaceutical dosage form (2017-09-05),

3. 8747900 - Dosage form with improved release of cefuroximaxetil (2014-06-10),

4. 8722086 - Dosage form with impeded abuse (2014-05-13),

5. 8383152 - Pharmaceutical dosage form (2013-02-26),

6. 8361506 - Fast release dosage forms for antibiotics (2013-01-29),

7. 8173164 - Oral administration forms for administering a fixed tramadol and diclofenac combination (2012-05-08),

8. 8147874 - Coated pellets (2012-04-03),

9. 7906141 - Sustained-release, oral pharmaceutical forms of formulation (2011-03-15),

10. 7897173 - Sustained-release, oral pharmaceutical formulations and methods of making and using same (2011-03-01),

11. 7666860 - Melt-formulated, multi-particulate oral dosage form (2010-02-23),

12. 7572463 - Oral dosage forms (2009-08-11),

13. 7410965 - Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol (2008-08-12),

14. 6576260 - Sustained-release form of administration containing tramadol saccharinate (2003-06-10),

15. 6558704 - Process for preparing pellets containing up to 90 wt.% of a pharmaceutical active ingredient (2003-05-06),

Title: The Innovative Contributions of Iris Ziegler

Introduction

Iris Ziegler is a prominent inventor based in Roetgen, Germany. She has made significant contributions to the field of pharmaceuticals, holding a total of 17 patents. Her work focuses on developing advanced pharmaceutical formulations that enhance the efficacy and release profiles of active ingredients.

Latest Patents

One of her latest patents is a prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol. This innovative formulation is designed for the controlled release of the active ingredient, ensuring a specific release rate over time. The composition allows for varying percentages of the active ingredient to be released at different intervals, providing a tailored therapeutic approach. The invention also emphasizes the importance of the pharmaceutical dosage form being tamper-resistant and possessing specific mechanical properties.

Career Highlights

Throughout her career, Iris Ziegler has worked with notable companies such as Grünenthal GmbH. Her expertise in pharmaceutical formulations has positioned her as a key player in the industry, contributing to advancements that benefit patient care and treatment outcomes.

Collaborations

Iris has collaborated with esteemed colleagues, including Johannes Heinrich Bartholomaeus and Johannes Bartholomäus. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Iris Ziegler's contributions to pharmaceutical innovation are noteworthy, with her patents reflecting a commitment to improving drug delivery systems. Her work continues to influence the field, paving the way for future advancements in pharmaceuticals.

Profile summary based on public USPTO records.